| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C88H128N12O19 |
| Purity | |
| Activity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
DBCO-PEG4-VC-PAB-MMAE combines an ADC linker (DBCO-PEG4-VC-PAB) with the tubulin polymerization inhibitor MMAE and can be used in the synthesis of antibody-agent conjugates (ADCs). MMAE, a synthetic derivative of dolastatin 10, acts as a potent mitotic inhibitor by blocking tubulin polymerization. As a click chemistry reagent, the compound carries a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. It is supplied as a white to off-white solid (C88H128N12O19, MW 1658.03) at 99.88% purity.
Physical & Chemical Properties
| CAS Number | 2129164-91-4 |
|---|---|
| Molecular Formula | C88H128N12O19 |
| Molecular Weight | 1658.03 g/mol |
| Purity | 99.88% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C(OCC3=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCOCCOCCOCCOCCNC(CCC(N4CC5=C(C=CC=C5)C#CC6=C4C=CC=C6)=O)=O)=O)=O)=O)C=C3)=O)C)=O)=O)C |
| Signaling Pathway | Antibody-Drug Conjugate/ADC Related |
| Bioactivity Class | Duocarmycins |
| Solubility | In Vitro: DMSO: ≥ 100 mg/mL (60.31 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) * "≥" means soluble, but saturation unknown. |
| Storage | -20°C, protect from light, stored under nitrogen. The compound is unstable in solutions, freshly prepared is recommended. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | ≥ 100 mg/mL (60.31 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
The manufacturer notes that the compound is unstable in solution; prepare solutions fresh before use.
Data provided by the manufacturer.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Tumor Microenvironment-Responsive Antibody Fragment-Cleavable PEGylated Drug Conjugates (AFCDC) for Improved Tumor Penetration and Antitumor Efficacy. J Med Chem 2026 Apr 29. PMID: 42055598
bioRxiv. 2026 May 12.
